Immunotherapy for early triple negative breast cancer: research agenda for the next decade.
Paolo TarantinoChiara CortiPeter SchmidJavier CortesElizabeth A MittendorfHope RugoSara M TolaneyGiampaolo BianchiniFabrice AndreCurigliano GiuseppePublished in: NPJ breast cancer (2022)
For decades, the systemic treatment of localized triple negative breast cancer (TNBC) has exclusively relied on chemotherapy. Recent advancements, however, are rapidly reshaping the treatment algorithms for this disease. The addition of pembrolizumab to neoadjuvant chemotherapy has indeed shown to significantly improve event-free survival for stage II-III TNBC, leading to its establishment as new standard of care in this setting. This landmark advancement has however raised several important scientific questions. Indeed, we desperately need strategies to identify upfront patients deriving benefit from the addition of immunotherapy. Moreover, the best integration of pembrolizumab with further recent advancements (capecitabine, olaparib) is yet to be defined. Lastly, extensive efforts are needed to minimize the impact on patients of immune-related adverse events and financial toxicity. The next decade of clinical research will be key to overcome these challenges, and ultimately learn how to optimally integrate immunotherapy in the treatment landscape of TNBC.
Keyphrases
- neoadjuvant chemotherapy
- end stage renal disease
- newly diagnosed
- ejection fraction
- locally advanced
- chronic kidney disease
- healthcare
- free survival
- prognostic factors
- radiation therapy
- advanced non small cell lung cancer
- oxidative stress
- clinical trial
- palliative care
- young adults
- phase ii study
- quality improvement
- pain management
- rectal cancer
- replacement therapy
- epidermal growth factor receptor
- chronic pain